220 related articles for article (PubMed ID: 19475687)
21. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
22. Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.
Buko VU; Lukivskaya OY; Naruta EE; Belonovskaya EB; Tauschel HD
J Clin Exp Hepatol; 2014 Dec; 4(4):293-301. PubMed ID: 25755576
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
24. 24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new "urso saga" on the horizon?
Chazouillères O
J Hepatol; 2017 Sep; 67(3):446-447. PubMed ID: 28676324
[No Abstract] [Full Text] [Related]
25. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
26. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
27. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
28. Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease.
Tang Y; Fickert P; Trauner M; Marcus N; Blomenkamp K; Teckman J
Am J Physiol Gastrointest Liver Physiol; 2016 Jul; 311(1):G156-65. PubMed ID: 27102560
[TBL] [Abstract][Full Text] [Related]
29. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
30. Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.
Yoon YB; Hagey LR; Hofmann AF; Gurantz D; Michelotti EL; Steinbach JH
Gastroenterology; 1986 Apr; 90(4):837-52. PubMed ID: 3949115
[TBL] [Abstract][Full Text] [Related]
31. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
32. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
[TBL] [Abstract][Full Text] [Related]
33. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
[TBL] [Abstract][Full Text] [Related]
34. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
35. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
36. Therapy with ursodeoxycholic acid in cholestatic liver disease.
Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
[TBL] [Abstract][Full Text] [Related]
37. NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.
Tang Y; Blomenkamp KS; Fickert P; Trauner M; Teckman JH
PLoS One; 2018; 13(8):e0200897. PubMed ID: 30067827
[TBL] [Abstract][Full Text] [Related]
38. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
Trauner M; Graziadei IW
Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
[TBL] [Abstract][Full Text] [Related]
39. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
40. Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion.
Fiorotto R; Spirlì C; Fabris L; Cadamuro M; Okolicsanyi L; Strazzabosco M
Gastroenterology; 2007 Nov; 133(5):1603-13. PubMed ID: 17983806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
